Koninklijke Philips Continues To Expects 3-5% Comparable Sales Growth And Adjusted EBITA Margin Of 11-11.5%; Sees Free Cash Flow Of EUR 0.9B-1.1B
Koninklijke Philips Continues To Expects 3-5% Comparable Sales Growth And Adjusted EBITA Margin Of 11-11.5%; Sees Free Cash Flow Of EUR 0.9B-1.1B
Outlook
外表
Philips reiterates its confidence in delivering the 2025 plan, acknowledging that uncertainties remain. For the full year 2024, Philips continues to expect 3-5% comparable sales growth and an Adjusted EBITA margin of 11-11.5%.
飛利浦重申了對實現2025年計劃的信心，承認不確定性仍然存在。飛利浦繼續預計，2024年全年可比銷售增長3-5％，調整後的息稅折舊攤銷前利潤率爲11-11.5％。
The expected free cash flow is now increased to EUR 0.9-1.1 billion in 2024, including the receipt from insurers for the Respironics product liability claims and the remaining payment related to the economic loss settlement.
現在，預期的自由現金流將在2024年增加到9-11億歐元，其中包括保險公司爲Respironics產品責任索賠收款以及與經濟損失和解相關的剩餘款項。
The personal injury and medical monitoring litigation settlement payment is expected in 2025. The outlook excludes the potential impact of other previously disclosed Philips Respironics-related legal proceedings, including the investigation by the US Department of Justice.
人身傷害和醫療監督訴訟和解金預計將在2025年支付。該展望不包括先前披露的其他飛利浦Respironics相關法律訴訟的潛在影響，包括美國司法部的調查。